Literature DB >> 30328215

Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement.

Lukas Weber1,2, Hans Rickli1, Philipp K Haager1, Lucas Joerg1, Daniel Weilenmann1, Roman Brenner1, Maurizio Taramasso3, Philipp Baier1, Francesco Maisano3, Micha T Maeder1.   

Abstract

AIMS: We aimed to investigate the prevalence, detailed invasive haemodynamics, and prognostic impact of pulmonary hypertension (PH) in severe aortic stenosis (AS). METHODS AND
RESULTS: We studied 503 patients (mean age 74 ± 10 years) with severe AS (indexed aortic valve area 0.4 ± 0.1 cm2 /m2 , left ventricular ejection fraction 57 ± 12%) undergoing left and right heart catheterization prior to aortic valve replacement. Median follow-up was 3.7 (interquartile range 2.6-5.4) years. Baseline PH (mean pulmonary artery pressure ≥ 25 mmHg) was found in 239 (48%) patients: 31 patients had pre-capillary PH [mean pulmonary artery wedge pressure (mPAWP) ≤ 15 mmHg], 144 had isolated post-capillary PH [IpcPH; mPAWP > 15 mmHg, pulmonary vascular resistance (PVR) ≤ 3 Wood units (WU)], and 64 had combined pre- and post-capillary PH (CpcPH; mPAWP > 15 mmHg, PVR > 3 WU). Patients with CpcPH had higher mortality than those with IpcPH, pre-capillary PH, and without PH. In the multivariate analysis, CpcPH remained an independent predictor of death (hazard ratio 4.39, 95% confidence interval 2.40-8.03; P < 0.001). Patients with CpcPH had higher mPAWP (26 ± 7 vs. 22 ± 5 mmHg) and lower pulmonary arterial capacitance (1.5 ± 0.6 vs. 2.9 ± 1.2 mL/mmHg) than IpcPH patients but similar left ventricular end-diastolic pressure (LVEDP; 25 ± 7 vs. 25 ± 7 mmHg). A smaller LVEDP-mPAWP difference was related to larger left atrial size, atrial fibrillation, and more severe mitral regurgitation.
CONCLUSIONS: In patients with severe AS, PH is common but underlying mechanisms differ. Patients with CpcPH have higher mPAWP, lower pulmonary arterial capacitance, and worse survival than all other groups. Left atrial dysfunction and mitral regurgitation seem to be drivers of high mPAWP in CpcPH.
© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.

Entities:  

Keywords:  Aortic stenosis; Post-capillary; Pre-capillary; Pulmonary capacitance; Pulmonary hypertension; Wedge pressure

Mesh:

Year:  2018        PMID: 30328215     DOI: 10.1002/ejhf.1322

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  11 in total

1.  Pulmonary arterial capacitance predicts outcomes in patients with pulmonary hypertension independent of race/ethnicity, sex, and etiology.

Authors:  Jacob J Mayfield; Alexander Papolos; Elena Vasti; Teresa De Marco; Geoffrey H Tison
Journal:  Respir Med       Date:  2020-02-04       Impact factor: 3.415

Review 2.  Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Elke Boxhammer; Alexander E Berezin; Vera Paar; Nina Bacher; Albert Topf; Sergii Pavlov; Uta C Hoppe; Michael Lichtenauer
Journal:  J Pers Med       Date:  2022-04-08

3.  Comparison of PCWP and LVEDP Measurements in Patients with Severe Aortic Stenosis Undergoing TAVI-Same Same but Different?

Authors:  Elke Boxhammer; Moritz Mirna; Laura Bäz; Brunilda Alushi; Marcus Franz; Daniel Kretzschmar; Uta C Hoppe; Alexander Lauten; Michael Lichtenauer
Journal:  J Clin Med       Date:  2022-05-25       Impact factor: 4.964

4.  Relationship between B-type natriuretic peptide and invasive haemodynamics in patients with severe aortic valve stenosis.

Authors:  Micha T Maeder; Lukas Weber; Peter Ammann; Marc Buser; Niklas F Ehl; Marc Gerhard; Roman Brenner; Philipp K Haager; Francesco Maisano; Hans Rickli
Journal:  ESC Heart Fail       Date:  2020-01-29

5.  Prediction of One-Year Mortality Based upon A New Staged Mortality Risk Model in Patients with Aortic Stenosis Undergoing Transcatheter Valve Replacement.

Authors:  Verena Veulemans; Amin Polzin; Oliver Maier; Kathrin Klein; Georg Wolff; Katharina Hellhammer; Shazia Afzal; Kerstin Piayda; Christian Jung; Ralf Westenfeld; Alexander Blehm; Artur Lichtenberg; Malte Kelm; Tobias Zeus
Journal:  J Clin Med       Date:  2019-10-08       Impact factor: 4.241

6.  Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival.

Authors:  Javier Bermejo; Ana González-Mansilla; Teresa Mombiela; Ana I Fernández; Pablo Martínez-Legazpi; Raquel Yotti; Rocío García-Orta; Pedro L Sánchez-Fernández; Mario Castaño; Javier Segovia-Cubero; Pilar Escribano-Subias; J Alberto San Román; Xavier Borrás; Angel Alonso-Gómez; Javier Botas; María G Crespo-Leiro; Sonia Velasco; Antoni Bayés-Genís; Amador López; Roberto Muñoz-Aguilera; Manuel Jiménez-Navarro; José R González-Juanatey; Arturo Evangelista; Jaime Elízaga; Javier Martín-Moreiras; José M González-Santos; Eduardo Moreno-Escobar; Francisco Fernández-Avilés
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

7.  Wedge Pressure vs Left Ventricular End-Diastolic Pressure for Pulmonary Hypertension Classification and Prognostication in Severe Aortic Stenosis.

Authors:  Micha T Maeder; Lukas Weber; Sebastian Seidl; Daniel Weilenmann; David Hochholzer; Lucas Joerg; Joannis Chronis; Johannes Rigger; Philipp K Haager; Hans Rickli
Journal:  CJC Open       Date:  2021-07-10

Review 8.  Non-Coding RNA Networks in Pulmonary Hypertension.

Authors:  Hongbin Zang; Qiongyu Zhang; Xiaodong Li
Journal:  Front Genet       Date:  2021-11-30       Impact factor: 4.599

9.  Impact of a volume challenge on haemodynamics and prognosis in patients with severe aortic stenosis.

Authors:  Micha T Maeder; Lukas Weber; Daniel Weilenmann; Philipp K Haager; Lucas Joerg; Franziska Rohner; Peter Ammann; Joannis Chronis; Johannes Rigger; Hans Rickli
Journal:  ESC Heart Fail       Date:  2020-11-12

10.  Soluble ST2 as a Potential Biomarker for Risk Assessment of Pulmonary Hypertension in Patients Undergoing TAVR?

Authors:  Elke Boxhammer; Moritz Mirna; Laura Bäz; Nina Bacher; Albert Topf; Brigitte Sipos; Marcus Franz; Daniel Kretzschmar; Uta C Hoppe; Alexander Lauten; Michael Lichtenauer
Journal:  Life (Basel)       Date:  2022-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.